Maja Davidson, MD
Endocrinology, Diabetes & Metabolism · Phoenix, AZNPI 1841555901
Payments from drug & device makers
Across 204 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$617
- Tandem Diabetes Care, Inc.$500
- Abbott$395
- AbbVie$321
- Insulet Corporation$259
- Sanofi-aventis U.S. LLC$234
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$50011%
- Food & beverage$3,85688%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 43 | $617 |
| Tandem Diabetes Care, Inc. | 2 | $500 |
| Abbott | 25 | $395 |
| AbbVie | 15 | $321 |
| Insulet Corporation | 10 | $259 |
| Sanofi-aventis U.S. LLC | 8 | $234 |
| Medtronic | 3 | $225 |
| Radius Health, Inc. | 12 | $225 |
| Boehringer Ingelheim | 11 | $193 |
| Amgen(2 entities) | 11 | $178 |
| Xeris Pharmaceuticals, Inc. | 8 | $150 |
| Dexcom, Inc. | 10 | $139 |
| Novo Nordisk | 8 | $133 |
| Embecta Corp. | 5 | $103 |
| Amneal Pharmaceuticals LLC | 5 | $91 |
| Corcept Therapeutics | 3 | $77 |
| Sequel Med Tech, LLC | 1 | $71 |
| Angiodynamics, Inc. | 1 | $68 |
| Ascendis Pharma Endocrinology Inc | 2 | $52 |
| Almatica Pharma LLC | 2 | $42 |
| Amphastar Pharmaceuticals, Inc. | 3 | $41 |
| Recordati_rare_diseases_inc. | 2 | $40 |
| Lifescan, Inc. | 2 | $39 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Verity Pharmaceuticals Inc. | 1 | $19 |
| Mannkind Corporation | 1 | $19 |
| BETA Bionics, Inc. | 2 | $19 |
| Nevro Corp. | 1 | $17 |
| Bayer | 1 | $15 |
| Echosens North America, Inc. | 1 | $15 |
| BD | 1 | $14 |
| Globus Medical | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 insulin pump$500
- MINIMED 780G$200
- TZIELD$125
How this compares
$4,368 in reported general payments places this provider in the 55th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 254 | $414,697 |
| TrulicityDulaglutide | 99 | $178,043 |
| JardianceEmpagliflozin | 115 | $174,533 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 109 | $168,065 |
| MounjaroTirzepatide | 122 | $159,282 |
| Humalog Kwikpen U-200Insulin Lispro | 62 | $114,331 |
| ProliaDenosumab | 42 | $72,596 |
| FarxigaDapagliflozin Propanediol | 61 | $59,542 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $57,542 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 49 | $47,026 |
| JanuviaSitagliptin Phosphate | 38 | $46,772 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 28 | $25,542 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 162 | $22,119 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $19,481 |
| Novolog FlexpenInsulin Aspart | 63 | $17,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $133 | $424,385284 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $617 | $351,755264 claims |
| Boehringer IngelheimJardiance | $193 | $174,533115 claims |
| AmgenProlia | $178 | $72,59642 claims |
| AstraZenecaFarxiga | $11 | $59,54261 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $234 | $36,68064 claims |
| AbbVieSynthroid | $321 | $11,904122 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $91 | $7,943702 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Phoenix
- Kevin YuenPhoenix$733K
- Joan BaileyPhoenix$316K
- Peter ReavenPhoenix$142K
- Sherman HarmanPhoenix$47K
- Anna BoronPhoenix$32K
- Kari EdlingPhoenix$23K
- Richard ArakakiPhoenix$20K
- James DeerPhoenix$13K
- Lory BarazPhoenix$10K
- Sathya JyothinagaramPhoenix$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.